← All trials
NCT05187182
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Mar 31, 2026
- Completion date
- Jan 31, 2027
- First posted
- Jan 11, 2022
- Last posted
- Sep 16, 2022
- Enrollment
- 42
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Washington University in St. LouisLead sponsor
- CurisCollaborator
- Washington University in St. LouisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.